Chemometec A/S
F:CHY

Watchlist Manager
Chemometec A/S Logo
Chemometec A/S
F:CHY
Watchlist
Price: 84.9 EUR -4.55% Market Closed
Market Cap: €1.5B

Gross Margin

83.1%
Current
Improving
by 3.1%
vs 3-y average of 80%

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
83.1%
=
Gross Profit
kr412m
/
Revenue
kr495.6m

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
83.1%
=
Gross Profit
€412m
/
Revenue
kr495.6m

Peer Comparison

Country Company Market Cap Gross
Margin
DK
Chemometec A/S
CSE:CHEMM
11.2B DKK
Loading...
US
PerkinElmer Inc
LSE:0KHE
1.3T USD
Loading...
US
Thermo Fisher Scientific Inc
NYSE:TMO
230.9B USD
Loading...
US
Danaher Corp
NYSE:DHR
160.2B USD
Loading...
KR
Samsung Biologics Co Ltd
KRX:207940
46.3T KRW
Loading...
CH
Lonza Group AG
SIX:LONN
37.9B CHF
Loading...
US
IQVIA Holdings Inc
NYSE:IQV
40.7B USD
Loading...
CN
WuXi AppTec Co Ltd
SSE:603259
274.7B CNY
Loading...
US
Agilent Technologies Inc
NYSE:A
38.1B USD
Loading...
US
Mettler-Toledo International Inc
NYSE:MTD
28.7B USD
Loading...
FR
Sartorius Stedim Biotech SA
PAR:DIM
19.2B EUR
Loading...

Market Distribution

Higher than 87% of companies in Denmark
Percentile
87th
Based on 447 companies
87th percentile
83.1%
Low
-2 199.8% — 26.7%
Typical Range
26.7% — 65.9%
High
65.9% — 1 637.7%
Distribution Statistics
Denmark
Min -2 199.8%
30th Percentile 26.7%
Median 45.7%
70th Percentile 65.9%
Max 1 637.7%

Chemometec A/S
Glance View

Chemometec A/S, a Danish firm founded in the late 1990s, has carved a niche in the specialized world of biotech instrumentation. The company is renowned for developing and manufacturing high-precision cell counting and analysis instruments used predominantly in the life sciences sector. Its flagship product, the NucleoCounter®, has gained significant traction in laboratories and production facilities worldwide. This product stands out due to its accuracy and ease of use in counting various types of cells, whether in research or pharmaceutical production settings. Unlike traditional methods, Chemometec’s technology enables researchers to save time and reduce error, which is invaluable for laboratories looking to enhance their workflow efficiencies. Revenue for Chemometec is primarily generated through the sale of its advanced instruments and associated consumables, along with providing expert services that support the integration and maintenance of these technologies. The company's business model capitalizes on the growing global demand for sophisticated biomedical research tools, as innovation in the drug development and biotechnology sectors accelerates. By continuously investing in R&D, Chemometec not only ensures its products remain cutting-edge but also expands its applicability across new areas in the life sciences field. The strategy of maintaining close relationships with its end-users ensures that as the scientific landscape evolves, Chemometec is well-positioned to adapt and grow.

CHY Intrinsic Value
63 EUR
Overvaluation 26%
Intrinsic Value
Price
What is Gross Margin?
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
How is Gross Margin calculated?

Gross Margin is calculated by dividing the Gross Profit by the Revenue.

Gross Margin
83.1%
=
Gross Profit
kr412m
/
Revenue
kr495.6m
What is Chemometec A/S's current Gross Margin?

The current Gross Margin for Chemometec A/S is 83.1%, which is above its 3-year median of 80%.

How has Gross Margin changed over time?

Over the last 3 years, Chemometec A/S’s Gross Margin has increased from 80.1% to 83.1%. During this period, it reached a low of 78.8% on Jun 30, 2024 and a high of 83.1% on Jul 30, 2025.

Back to Top